Adolescent Mental HealthNCT07700264
A Validation Study of the Neuro-cognitive Emotion Monitoring-Intervention (NEMO-I) Application in Adolescents
A study testing NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention) in people with Adolescent Mental Health and Adolescent - Emotional Problem, run by Seoul Women's University at 1 site in South Korea.
Trial summary
This study aims to evaluate the validity and effectiveness of NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention), a mobile application designed to help adolescents monitor and manage their cognitive and emotional functioning in everyday settings. Read more about this study
- Who is it for?
- Ages 12 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Adolescent Mental Health, Adolescent - Emotional Problem, Cognition Improvement
- What is being tested?
- NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 140 participants
- Where
- 1 siteSouth Korea
- Study dates
- 10 Jul 2026to 30 Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Middle or high school students currently enrolled in school
- Using an Android-based smartphone
- Voluntary agreement to participate, with consent from a legal guardian
Who cannot join
- Borderline intellectual functioning or intellectual disability (IQ below 80)
- Visual or hearing impairment
- Prior diagnosis of intellectual, visual, or hearing impairment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site
Seoul Women's University
Seoul, Seoul, 01797
Myeongjie Im, MA, +82-10-2588-0859, imj@swu.ac.kr
Hyunjoo Song, PhD
About this study
This study aims to evaluate the validity and effectiveness of NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention), a mobile application designed to help adolescents monitor and manage their cognitive and emotional functioning in everyday settings. NEMO-I delivers evidence-based psychological techniques-such as mindfulness, self-regulation training, and emotion monitoring-in a gamified format consisting of seven brief activities that users can complete at home in about 10 minutes each.
A total of 140 middle and high school students will participate. Participants will complete standardized neuropsychological and psychological assessments before and after the intervention period. During the 21-day intervention period, participants will use the NEMO-I application at home each day at their convenience (a minimum of 10 minutes per day is recommended). By comparing pre- and post-intervention assessment results, this study seeks to determine whether the application produces meaningful benefits for adolescent mental health and to establish its suitability as a digital mental health tool.
- Being tested
- NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention)
- Keywords
- Digital mental health intervention, adolescents, mobile based intervention, emotion, cognitive function, NEMO-I
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention)Behavioural
NEMO-I is a mobile application that delivers evidence-based psychological techniques in a gamified format. It consists of seven brief activities-including facial expression imitation, singing, breathing and stretching with nature sounds, reading tips for everyday concerns, rhythm-based instrument play, room decoration, and mindfulness-each designed to be completed at home in about 10 minutes. Participants use the application daily during the 21-day intervention period, at their convenience, with a recommended minimum of 10 minutes per day.
| Study group | Role | What they receive |
|---|---|---|
| NEMO-I Intervention Group | Experimental | Participants in this single-arm study use the NEMO-I mobile application at home for 21 days, at their convenience each day (a minimum of 10 minutes per day is recommended). Cognitive and emotional outcomes are assessed before and after the intervention period. Receives: Behavioral: NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in depressive symptoms
Depressive symptoms are measured using the Beck Depression Inventory-II (BDI-II), a 21-item self-report questionnaire. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms. Change is assessed by comparing pre- and post-intervention scores.
Measured: Baseline (pre-intervention) and after the 21-day intervention period
Change in inhibitory control (Color-Word Stroop Test, CWST)
Inhibitory control is assessed using the Color-Word Stroop Test (CWST), which measures the efficiency of the frontal-lobe inhibition process. Performance is indexed by response time and error rate under the color-word interference condition. Change is assessed by comparing pre- and post-intervention performance.
Measured: Baseline(pre-intervention) and after the 21-day intervention period
Change in anxiety symptoms
Anxiety symptoms are measured using the Beck Anxiety Inventory (BAI), a 21-item self-report questionnaire assessing the severity of anxiety-related symptoms. Higher scores indicate greater anxiety. Change is assessed by comparing pre- and post-intervention scores.
Measured: Baseline(pre-intervention) and after the 21-day intervention period
Change in neuro-cognitive and emotional function (NEMO-A)
Neuro-cognitive and emotional function is assessed using the NEMO-A (Neuro-cognitive Emotion Monitoring-Assessment) application, a tablet-based, game-format assessment consisting of five subtasks. It measures domains including sustained attention, working memory, emotional sensitivity, emotion processing and recognition, audiovisual emotional integration, cognitive control, and executive function. Performance is indexed by accuracy and response time, and change is assessed by comparing pre- and post-intervention performance.
Measured: Baseline (pre-intervention) and after the 21-day intervention period
Change in visual attention and processing speed (Children's Color Trails Test, CCTT)
Visual attention, psychomotor speed, sequential processing, and divided/sustained visual attention are assessed using the Children's Color Trails Test (CCTT). Performance is indexed by completion time (seconds). Change is assessed by comparing pre- and post-intervention performance.
Measured: Baseline (pre-intervention) and after the 21-day intervention period
Change in set-shifting ability (Trail Making Test-B, TMT-B)
Set-shifting ability and cognitive flexibility are assessed using the Trail Making Test-B (TMT-B), which requires alternating between numbers and letters in sequence. Performance is indexed by completion time (seconds). Change is assessed by comparing pre- and post-intervention performance.
Measured: Baseline (pre-intervention) and after the 21-day intervention period
Secondary outcomes (7)
Change in subjective stress
Subjective stress is measured using a Visual Analog Scale (VAS), on which participants rate their current perceived stress level from 1 (no stress) to 10 (extreme stress).
Measured: Baseline (pre-intervention) and after the 21-day intervention period
Change in daily stress
Daily stress is measured using a 26-item self-report scale assessing stress experienced in everyday domains such as parents, school, academics, peer relationships, appearance, and finances, rated on a 5-point Likert scale.
Measured: Baseline(pre-intervention) and after the 21-day intervention period
Change in alexithymia
Difficulty identifying and describing one's own emotions is measured using the Korean version of the 20-item Toronto Alexithymia Scale (TAS-20K), rated on a 5-point Likert scale.
Measured: Baseline (pre-intervention) and after the 21-day intervention period
Change in executive function difficulties (self-report)
Self-reported executive function difficulties are measured using the Brief Self-Report Questionnaire of Executive Function Difficulty for children and adolescents (40 items), rated on a 3-point Likert scale.
Measured: Baseline (pre-intervention) and after the 21-day intervention period
Change in peer relationship quality
The quality of peer relationships is measured using a 13-item self-report scale rated on a 4-point Likert scale, including items reflecting conflict and negative peer interactions.
Measured: Baseline (pre-intervention) and after the 21-day intervention period
Change in problem behaviors (CBCL 6-18, parent report)
Problem behaviors are assessed using the Child Behavior Checklist for Ages 6-18 (CBCL 6-18), completed by a parent or primary caregiver. It includes internalizing problems (e.g., anxiety, depression, somatic complaints) and externalizing problems (e.g., rule-breaking, aggressive behavior).
Measured: Baseline (pre-intervention) and after the 21-day intervention period
Change in ADHD symptoms (ARS, parent report)
Attention-deficit/hyperactivity symptoms are assessed using the ADHD Rating Scale (ARS), an 18-item parent-report questionnaire comprising inattention and hyperactivity/impulsivity subscales.
Measured: Baseline (pre-intervention) and after the 21-day intervention period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start10 Jul 2026 (estimated)
- Primary completion28 Feb 2027 (estimated)
- Study completion30 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adolescent Mental HealthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 140 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seoul Women's University
- Sponsor type
- University, hospital or other
- Collaborators
- Korea Health Industry Development Institute, Ministry of Health & Welfare, Korea
- Responsible party
- Sponsor
- Investigators
- Hyunjoo Song, PhD, Principal investigator, Seoul Women's University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07700264
- Sponsor's protocol ID
- SWU-2605-004
- Other IDs
- RS-2022-KH126068
- Status last verified
- Jul 2026
- First submitted
- 2 Jul 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared with other researchers, as participants and their legal guardians were informed during the informed consent process that collected data would not be provided to third parties.
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Validation Study of the Neuro-cognitive Emotion Monitoring-Intervention (NEMO-I) Application in Adolescents
- ClinicalTrials.gov ID
- NCT07700264
- Acronym / sponsor ID
- SWU-2605-004
- Keywords
- Digital mental health intervention, adolescents, mobile based intervention, emotion, cognitive function, NEMO-I
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 140 participants (estimated)
- Lead sponsor
- Seoul Women's UniversityUniversity, hospital or other
- Collaborators
- Korea Health Industry Development Institute, Ministry of Health & Welfare, Korea
- Study start
- 10 Jul 2026 (estimated)
- Primary completion
- 28 Feb 2027 (estimated)
- Study completion
- 30 Apr 2027 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the validity and effectiveness of NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention), a mobile application designed to help adolescents monitor and manage their cognitive and emotional functioning in everyday settings. NEMO-I delivers evidence-based psychological techniques-such as mindfulness, self-regulation training, and emotion monitoring-in a gamified format consisting of seven brief activities that users can complete at home in about 10 minutes each.
A total of 140 middle and high school students will participate. Participants will complete standardized neuropsychological and psychological assessments before and after the intervention period. During the 21-day intervention period, participants will use the NEMO-I application at home each day at their convenience (a minimum of 10 minutes per day is recommended). By comparing pre- and post-intervention assessment results, this study seeks to determine whether the application produces meaningful benefits for adolescent mental health and to establish its suitability as a digital mental health tool.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| NEMO-I Intervention Group | Experimental | Behavioral: NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention)Participants in this single-arm study use the NEMO-I mobile application at home for 21 days, at their convenience each day (a minimum of 10 minutes per day is recommended). Cognitive and emotional outcomes are assessed before and after the intervention period. |
Who may qualify
- Ages
- 12 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Middle or high school students currently enrolled in school
- Using an Android-based smartphone
- Voluntary agreement to participate, with consent from a legal guardian
Key exclusion criteria (3 listed)
- Borderline intellectual functioning or intellectual disability (IQ below 80)
- Visual or hearing impairment
- Prior diagnosis of intellectual, visual, or hearing impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention)NEMO-I is a mobile application that delivers evidence-based psychological techniques in a gamified format. It consists of seven brief activities-including facial expression imitation, singing, breathing and stretching with nature sounds, reading tips for everyday concerns, rhythm-based instrument play, room decoration, and mindfulness-each designed to be completed at home in about 10 minutes. Participants use the application daily during the 21-day intervention period, at their convenience, with a recommended minimum of 10 minutes per day. | Behavioural | NEMO-I Intervention Group |
Primary outcome
Change in depressive symptoms
Time frame: Baseline (pre-intervention) and after the 21-day intervention period
Depressive symptoms are measured using the Beck Depression Inventory-II (BDI-II), a 21-item self-report questionnaire. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms. Change is assessed by comparing pre- and post-intervention scores.
Change in inhibitory control (Color-Word Stroop Test, CWST)
Time frame: Baseline(pre-intervention) and after the 21-day intervention period
Inhibitory control is assessed using the Color-Word Stroop Test (CWST), which measures the efficiency of the frontal-lobe inhibition process. Performance is indexed by response time and error rate under the color-word interference condition. Change is assessed by comparing pre- and post-intervention performance.
Change in anxiety symptoms
Time frame: Baseline(pre-intervention) and after the 21-day intervention period
Anxiety symptoms are measured using the Beck Anxiety Inventory (BAI), a 21-item self-report questionnaire assessing the severity of anxiety-related symptoms. Higher scores indicate greater anxiety. Change is assessed by comparing pre- and post-intervention scores.
Change in neuro-cognitive and emotional function (NEMO-A)
Time frame: Baseline (pre-intervention) and after the 21-day intervention period
Neuro-cognitive and emotional function is assessed using the NEMO-A (Neuro-cognitive Emotion Monitoring-Assessment) application, a tablet-based, game-format assessment consisting of five subtasks. It measures domains including sustained attention, working memory, emotional sensitivity, emotion processing and recognition, audiovisual emotional integration, cognitive control, and executive function. Performance is indexed by accuracy and response time, and change is assessed by comparing pre- and post-intervention performance.
Change in visual attention and processing speed (Children's Color Trails Test, CCTT)
Time frame: Baseline (pre-intervention) and after the 21-day intervention period
Visual attention, psychomotor speed, sequential processing, and divided/sustained visual attention are assessed using the Children's Color Trails Test (CCTT). Performance is indexed by completion time (seconds). Change is assessed by comparing pre- and post-intervention performance.
Change in set-shifting ability (Trail Making Test-B, TMT-B)
Time frame: Baseline (pre-intervention) and after the 21-day intervention period
Set-shifting ability and cognitive flexibility are assessed using the Trail Making Test-B (TMT-B), which requires alternating between numbers and letters in sequence. Performance is indexed by completion time (seconds). Change is assessed by comparing pre- and post-intervention performance.
7 secondary outcomes
Change in subjective stress
Time frame: Baseline (pre-intervention) and after the 21-day intervention period
Change in daily stress
Time frame: Baseline(pre-intervention) and after the 21-day intervention period
Change in alexithymia
Time frame: Baseline (pre-intervention) and after the 21-day intervention period
Change in executive function difficulties (self-report)
Time frame: Baseline (pre-intervention) and after the 21-day intervention period
Change in peer relationship quality
Time frame: Baseline (pre-intervention) and after the 21-day intervention period
Change in problem behaviors (CBCL 6-18, parent report)
Time frame: Baseline (pre-intervention) and after the 21-day intervention period
Change in ADHD symptoms (ARS, parent report)
Time frame: Baseline (pre-intervention) and after the 21-day intervention period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared with other researchers, as participants and their legal guardians were informed during the informed consent process that collected data would not be provided to third parties.
Related trials for Adolescent Mental Health
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Not yet recruiting
Advancing Cardiovascular Health Among Adolescents With Intellectual Disabilities: Co-Development of Technology Interventions to Enhance Physical Activity
Physical Activity, Intellectual Disabilities
Recruiting
Our Voices Matter: Intervention for Depression in Youth
Depressive Symptoms, Allostatic Load
Not yet recruiting
Development, Implementation, and Evaluation of the HADAS Program for the Prevention of Eating Disorders in Adolescent Female Athletes, Coaches, and Families.
Eating Disorders, Body Image Dissatisfaction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hyunjoo Song, PhD principal investigator
Seoul Women's University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention) in people with Adolescent Mental Health and Adolescent - Emotional Problem, run by Seoul Women's University at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Myeongjie Im, MA (+82-10-2588-0859, imj@swu.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in depressive symptoms (time frame: Baseline (pre-intervention) and after the 21-day intervention period). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.